Predictive Oncology Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update

NEXT STORY
Basilea reports significantly increased cash-generating revenue, flat operating expenses and reduced net loss for half-year 2019
PREV STORY
The Power of Real-World Data to Drive Outcomes
Subscribe to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063 in combination with anti-PD-1 Antibody Ezabenlimab, in Patients with Advanced Endometrium or Colorectal Tumors

author_avatar
NASDAQ Market News

BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma

author_avatar
NASDAQ Market News

CURE Pharmaceutical Subsidiary, Oak Therapeutics, Completes Critical Milestone in Phase 1 of NIH Grant to Develop Oral Dissolvable Strip for Tuberculosis

OXNARD, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading ...

author_avatar
NASDAQ Market News